Cargando…

Antiplatelet Therapy and Percutaneous Coronary Interventions

Dual antiplatelet therapy is one of the cornerstones of modern percutaneous coronary interventions. The development of new therapeutic agents has significantly reduced ischemic events at the risk of increased bleeding complications. Therefore, efforts are currently focused on optimizing therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davanzo, Rene Hameau, Alarcón, Alberto Fuensalida, Calquín, Jorge Quitral, Varela, Pablo Sepúlveda, Sepúlveda, Alejandro Martínez, Herreros, Ramón Corbalán, Patel, Sanjay, Rodríguez, Gonzalo Martínez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640857/ https://www.ncbi.nlm.nih.gov/pubmed/32538731 http://dx.doi.org/10.2174/1573403X16666200615144423

Ejemplares similares

Angioplastias da Artéria Mamária Interna Esquerda e Direita em Paciente de 3 Anos com Doença de Kawasaki e Falha na Cirurgia de Revascularização do Miocárdio
por: Hameau, René, et al.
Publicado: (2020)

Preoperative soluble VCAM‐1 contributes to predict late mortality after coronary artery surgery
por: Corbalan, Ramon, et al.
Publicado: (2020)

Intensity of antiplatelet therapy and percutaneous coronary intervention
por: Aronow, Wilbert S
Publicado: (2009)

Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
por: ten Berg, Jurriën M, et al.
Publicado: (2001)

Income and antiplatelet adherence following percutaneous coronary intervention
por: LaRosa, Anna R., et al.
Publicado: (2022)

Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions
por: Summaria, Francesco, et al.
Publicado: (2015)

Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention
por: Wisløff, Torbjørn, et al.
Publicado: (2016)

Neutrophil-derived microparticles are released into the coronary circulation following percutaneous coronary intervention in acute coronary syndrome patients
por: Martínez, Gonzalo J., et al.
Publicado: (2017)

Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
por: Han, Jennie, et al.
Publicado: (2021)

Oral antiplatelet therapy in the elderly undergoing percutaneous coronary intervention: an umbrella review
por: Biondi-Zoccai, Giuseppe, et al.
Publicado: (2020)

Focal Arterialization and Neoatherosclerosis of a Saphenous Vein Graft. Improving our Understanding of Late Graft Failures
por: Rene Hameau, D, et al.
Publicado: (2016)

Takotsubo syndrome - different presentations for a single disease: A case report and review of literature
por: Fuensalida, Alberto, et al.
Publicado: (2018)

Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome
por: Chen, Shih-Chin, et al.
Publicado: (2014)

Duration of dual antiplatelet therapy in patients treated with percutaneous coronary intervention for coronary chronic total occlusion
por: Lee, Seung Hwa, et al.
Publicado: (2017)

Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry
por: Christ, Günter, et al.
Publicado: (2014)

Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic review
por: Elliott, Jesse, et al.
Publicado: (2019)

Hyphema: A Rare Complication of Periprocedural Antiplatelets and Anticoagulants Following Percutaneous Coronary Intervention
por: Gulati, Amit, et al.
Publicado: (2021)

Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Short Is Too Short?
por: Mourikis, Philipp, et al.
Publicado: (2023)

From Coronaries to Cirrhosis: The Role of Percutaneous Coronary Intervention and Dual Antiplatelet Therapy in End-Stage Liver Disease
por: Remillard, Taylor C., et al.
Publicado: (2021)

Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US
por: Wang, Yehua, et al.
Publicado: (2023)

A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Li, Yachao, et al.
Publicado: (2023)

Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
por: Han, Jialun, et al.
Publicado: (2023)

Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention
por: Patel, Vardhaman, et al.
Publicado: (2014)

Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review
por: Elliott, Jesse, et al.
Publicado: (2017)

The Optimal Strategy of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stent
por: Hu, Mengjin, et al.
Publicado: (2022)

Shortening Dual Antiplatelet Therapy Duration in High-Risk Patients Undergoing Percutaneous Coronary Intervention
por: Greco, Antonio, et al.
Publicado: (2023)

Duration and clinical outcomes of dual antiplatelet therapy following percutaneous coronary intervention for acute coronary syndrome: A multicentre “real-world practice” registry-based study
por: Vergara-Uzcategui, Carlos E., et al.
Publicado: (2023)

Association of Frailty With Antiplatelet Response Among Elderly Chinese Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
por: Liu, Yang, et al.
Publicado: (2020)

Meta-analysis of Unguided Deescalation of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Mohamed, Mohamed M. G., et al.
Publicado: (2022)

Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention
por: Vaidya, Kaivan, et al.
Publicado: (2020)

The effect of early dual antiplatelet timing on the microvascular resistance and ventricular function in primary percutaneous coronary intervention
por: Firman, Doni, et al.
Publicado: (2020)

Extended Duration of Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long?
por: Howard, Charles E., et al.
Publicado: (2019)

Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
por: Ki, You-Jeong, et al.
Publicado: (2021)

Percutaneous Coronary Intervention With Dual Antiplatelet Therapy in a Patient With Chronic Subdural Hematoma: Novel Approach
por: Etuk, Aniekeme S, et al.
Publicado: (2022)

Triple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: A meta-analysis
por: ZHOU, HONG, et al.
Publicado: (2013)

Percutaneous Nephrolithotomy in Patients on Chronic Anticoagulant/Antiplatelet Therapy
por: Nerli, R B, et al.
Publicado: (2012)

The Use of Triphenyl Phosphonium Cation Enhances the Mitochondrial Antiplatelet Effect of the Compound Magnolol
por: Tellería, Francisca, et al.
Publicado: (2023)

Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents
por: Wang, Huili, et al.
Publicado: (2015)

The Role of Novel Oral Anticoagulants and Antiplatelet Therapy after Percutaneous Coronary Intervention: Individualizing Therapy to Optimize Outcomes
por: Shlofmitz, Evan, et al.
Publicado: (2019)

Impact of Routine Platelet Reactivity Testing with VerifyNow Assay on Antiplatelet Choice After Percutaneous Coronary Intervention
por: Mshelbwala, Fakilahyel S, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9q5hegbl5cnj4qattlrss6cpl9